New injection for high cholesterol begins first human safety tests
NCT ID NCT07241923
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial is testing a new injection called SYH2070 in 48 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure blood fat levels. This is an early step to see if the drug might one day help lower high triglycerides and cholesterol.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYH2070 injection
What this could lead to
If this early study shows the drug is safe, it could lead to larger trials testing whether SYH2070 can lower high triglycerides and cholesterol.
What could go wrong
This is a very early, small phase 1 trial in healthy people, not patients. The drug may not work or could have side effects. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS (HS) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trials Information Group
RECRUITINGShijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••